References of "Bastos da Silva, Miriam"
     in
Bookmark and Share    
See detailAerossolterapia nas doenças respiratórias em eqüinos
Bastos da Silva, Miriam; Duvivier, Dominique Hannia; Votion, Dominique ULg et al

in Brazilian Journal of Veterinary Research and Animal Science (2001), 38(2), 88-96

Respiratory problems are frequently implicated in horses as a cause of poor sportive performances. The most frequently occurring lower respiratory tract disorders are chronic obstructive pulmonary disease ... [more ▼]

Respiratory problems are frequently implicated in horses as a cause of poor sportive performances. The most frequently occurring lower respiratory tract disorders are chronic obstructive pulmonary disease (COPD), inflammatory airway disease and exercise-induced pulmonary haemorrhage (EIPH). Classically, their treatment includes systemic administration of drugs, but aerosol therapy is now known to be a more specific way to treat these disorders. This article describes the equipment and drugs currently available for aerosol therapy in horses. [less ▲]

Detailed reference viewed: 82 (1 ULg)
Full Text
See detailIn Vitro Inhibitory Effect of SR 27417, a Potent Platelet-Activating Factor (PAF) Receptor Antagonist, on the PAF-Induced Bovine Platelet Aggregation
Bastos da Silva, Miriam; Delaunois, Annie ULg; Gustin, Pascal ULg et al

in Veterinary Research (2000), 31(2, Mar-Apr), 267-672

The in vitro inhibitory effect of SR 27417, an antagonist of the platelet-activating factor (PAF) receptor, on PAF-induced platelet aggregation was studied in blood collected from seven healthy Friesien ... [more ▼]

The in vitro inhibitory effect of SR 27417, an antagonist of the platelet-activating factor (PAF) receptor, on PAF-induced platelet aggregation was studied in blood collected from seven healthy Friesien calves. Inhibitory effects of SR 27417 were determined at thirteen different concentrations (0.1-400 nM) by using the dose-response curves of PAF on calf platelet aggregation. In the presence of SR 27417, the maximal slopes of aggregation (%/min) induced by low and high concentrations of PAF were significantly different from the control values obtained without an antagonist at p < or = 0.05 and p < or = 0.01 respectively. In vitro PAF-induced calf platelet aggregation was dose-dependently inhibited by SR 27417. The drug inhibited PAF-induced platelet aggregation in a competitive reversible manner (pA2 = 10.46 +/- 2.36 mol x L(-1)). In conclusion, the results of our study showed that addition of SR 27417 to bovine platelet in vitro inhibits PAF-induced platelet aggregation. [less ▲]

Detailed reference viewed: 55 (2 ULg)
Full Text
See detailProtective Effects of Web 2086 (Paf Antagonist) and Ketoprofen (Nsaid) on Paf-Induced Changes in the Morphological Ultrastructure of Blood Platelets in Calves
Bastos da Silva, Miriam; Doizé, Cécile ULg; Coghe, Joost et al

in Veterinary Research Communications (1998), 22(4), 273-291

The ultrastructure of bovine platelets was examined by transmission electron microscopy without any pretreatment (control), and after WEB 2086 (a triazolodiazepine) or ketoprofen (NSAID) pretreatment ... [more ▼]

The ultrastructure of bovine platelets was examined by transmission electron microscopy without any pretreatment (control), and after WEB 2086 (a triazolodiazepine) or ketoprofen (NSAID) pretreatment, followed by PAF infusion. The blood platelet count was also investigated. The group of calves that received WEB 2086 pretreatment before platelet-activating factor (PAF) infusion did not show a decreased number of platelets. However, in the other group, with ketoprofen pretreatment before PAF infusion, there was a rapid decrease from 1 to 3 min, while from 5 min the number of platelets recovered to the normal value. Electron microscopy revealed that pretreatment with WEB 2086 followed by PAF infusion did not alter the morphological ultrastructure of bovine platelets, except that the microtubules were briefly modified from 1 until 3 min after PAF challenge. After ketoprofen pretreatment, bovine platelets kept their regular shape, the number of dense bodies was not significantly altered, the number of mitochondria was maintained from 5 min after PAF infusion, giant platelets were not observed and the Golgi apparatus was rarely visible. Thus pretreatment with WEB 2086 and ketoprofen before PAF infusion had a protective activity on the ultrastructure of bovine platelets and, in cattle, pretreatment with WEB 2086 and ketoprofen before PAF challenge prevented the thrombocytopenia induced by PAF. [less ▲]

Detailed reference viewed: 54 (1 ULg)
Full Text
See detailEffect of Ketoprofen on Paf-Induced Bovine Platelet Aggregation
Bastos da Silva, Miriam; Gustin, Pascal ULg; Herion, Francine ULg et al

in Veterinary Journal (1998), 155(2), 201-203

Detailed reference viewed: 26 (0 ULg)
Full Text
See detailMorphological alterations of blood platelets induced by Platelet Activating Factor (PAF) and partial inhibition by Ketoprofen in calves
Bastos da Silva, Miriam; Doizé, Cécile ULg; David, Jean-Louis ULg et al

in Veterinary Research (1997), 28(5 Sep-Oct), 489-502

The influence of platelet activating factor (PAF) was investigated in vivo on the ultrastructure of bovine platelets, and on the platelet count. The effect of an intravenous administration of ketoprofen ... [more ▼]

The influence of platelet activating factor (PAF) was investigated in vivo on the ultrastructure of bovine platelets, and on the platelet count. The effect of an intravenous administration of ketoprofen (a non-steroidal anti-inflammatory drug) pretreatment followed by PAF infusion was also observed in a group of six healthy male Friesian calves. PAF infusion alone caused a moderate thrombocytopenia, which peaked one minute post challenge and returned to levels not significantly different from control after 30 min. Electron microscopy revealed that after PAF infusion, platelets lost their lentiform shape and became irregular, with many pseudopods. Their microtubules became impossible to distinguish. The numbers of alpha granules and dense bodies were significantly decreased. Glycogen particles became rare or even disappeared. Giant platelets occasionally appeared. The Golgi apparatus was more often visible and the number of mitochondria was significantly increased. Ketoprofen pretreatment lowered PAF-induced thrombocytopenia and decrease in the number of dense bodies. Under these conditions, the Golgi apparatus was rarely visible and giant platelets were not observed. These results showed that the morphological ultrastructure of blood platelets in bovines were modified following PAF infusion and that ketoprofen pretreatment before PAF infusion provided partial protection, limiting the extent of the morphological alterations and maintaining a normal platelet count [less ▲]

Detailed reference viewed: 20 (2 ULg)
Full Text
See detailThe Effect of Intravenous Administration of Web 2086 on Paf-Induced Platelet Aggregation in Healthy Friesian Calves
Bastos da Silva, Miriam; Gustin, Pascal ULg; Herion, Francine ULg et al

in Veterinary Research Communications (1997), 21(7), 521-531

The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet ... [more ▼]

The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet aggregation curves. WEB 2086 was infused intravenously into a group of 5 healthy male Friesian calves in a dose of 3 mg/kg over 1 min. The resultant inhibition peaked between 30 min and 1 h after administration of WEB 2086. The inhibition was significantly reduced after 3 h and became non-significant after 6 h, but maximal pre-treatment aggregation had not been restored by 24 h after the injection of WEB 2086. These results confirm previous results obtained in vitro and suggest that WEB 2086 is a potent antagonist of PAF activity in calves. They also suggest that further clinical studies with WEB 2086 in cattle are desirable. [less ▲]

Detailed reference viewed: 29 (4 ULg)
Full Text
See detailCombined Effect of Web 2086 (Paf Antagonist) and Ketoprofen (Nsaid) on Paf-Induced Ex Vivo Platelet Aggregation in Bovine
Bastos da Silva, Miriam; Herion, Francine ULg; Raskinet, Renée ULg et al

in Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine (1997), 44(2), 65-71

The effect of the specific PAF-antagonist WEB 2086, a thieno-triazolo-diazepine, and ketoprofen, a NSAID, was investigated on PAF-induced bovine platelet aggregation measured ex vivo in platelet-rich ... [more ▼]

The effect of the specific PAF-antagonist WEB 2086, a thieno-triazolo-diazepine, and ketoprofen, a NSAID, was investigated on PAF-induced bovine platelet aggregation measured ex vivo in platelet-rich plasma (PRP). WEB 2086 was infused intravenously over 1 min followed immediately by ketoprofen administration over 1 s (both drugs = 3 mg/kg), in a group of six healthy male Friesian calves. Depending on the PAF concentration, a reversible (10(-8)-10(-9) mol/l) and irreversible (10(-5)-10(-7) mol/l) platelet aggregation was observed. The reversible aggregation was completely blocked by pretreatment of the animal with WEB 2086 and ketoprofen. The inhibitory effects observed during the irreversible aggregation were 47.22%, 54.00% and 88.00% at 10(-5), 10(-6) and 10(-7) mol/l PAF, respectively. Moreover, the aggregation obtained in these condition became reversible. Maximal inhibitory effect of WEB 2086 and ketoprofen on PAF-induced platelet aggregation in calves was observed within 30 min after administration of both drugs. This inhibition persisted even after 24 h and was significantly different from control with P < 0.05. The combined effect of both drugs exceeded the sum of the individual effects (synergism). It was concluded that WEB 2086 and ketoprofen very effectively blocked PAF-induced bovine platelet aggregation in platelet-rich plasma. The study also suggested a synergism between both substances. [less ▲]

Detailed reference viewed: 42 (0 ULg)
Full Text
See detailInhibition of Paf-Induced Platelet Aggregation by Web 2086 'in-Vitro', an Antagonist to the Receptor for Platelet-Activating Factor, in Bovine
Bastos da Silva, Miriam; Herion, Francine ULg; Raskinet, Renée ULg et al

in Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine (1996), 43(7), 399-413

The sensitivity of bovine platelet aggregation in response to PAF stimulation and the ability of WEB 2086 (a thieno-triazolodiazepine) to inhibit response to PAF-induced platelet aggregation were ... [more ▼]

The sensitivity of bovine platelet aggregation in response to PAF stimulation and the ability of WEB 2086 (a thieno-triazolodiazepine) to inhibit response to PAF-induced platelet aggregation were investigated in the blood from five healthy male Belgian Blue calves. The recorded response to PAF showed a plateau which was dependent on the PAF concentration. Platelet aggregation induced by PAF consists of two mechanisms: reversible and irreversible aggregations which are accompanied by the release of platelet granule contents. Reversible aggregation occurred above (2 . 10(-9) mol/l) PAF, and irreversible aggregation occurred above (2 . 10(-7) mol/l) PAF. Addition of WEB 2086 to bovine platelets in vitro induced a rightward shift in the dose-response curve to PAF. WEB 2086 inhibited PAF-induced aggregation in a competitive reversible manner (pA2 = 7.61). The results of our study show that PAF induces platelet aggregation in platelet-rich plasma (PRP) and that addition of WEB 2086 to bovine platelets in vitro inhibits PAF-induced Platelet Aggregation. [less ▲]

Detailed reference viewed: 47 (2 ULg)